Pacific Green Achieves Planning Permit for 1GW / 2.5GWh Portland Energy Park

Notified -

Angelini Pharma Signs Exclusive Option Agreement With Sovargen To License Global Development and Commercialization Rights For Innovative Brain Health Asset

Notified -

YY Group Announces Strategic Expansions Into Netherlands, Strengthening its EU Presence

[img]http://phpstack-1214942-4313335.cloudwaysapps.com/api/ImageRender/DownloadFile?resourceId=dc77fed3-cad2-44b2-874b-14ce06028b24&size=3[/img]Notified -

Coventry Celebrates the Power, Flexibility, and Value of Life Insurance During Life Insurance Awareness Month

Notified -

Shamrock V awarded 5 Stars by the SEA Index at Monaco Classic Week

Notified -

First European Participants Randomized in AskBio Phase 2 Gene Therapy Trial of AB-1005 for Parkinson’s Disease

Notified -

WeRide to Launch GXRs and Robobus in Singapore as part of Grab's New Ai.R Autonomous Service

Notified -

Axi Announces Retirement of Chief Commercial Officer Louis Cooper

Notified -

OPEC Fund mobilizes over US$1 billion to advance sustainable development

Notified -

WHO Disenfranchises the Public from Tobacco Control Conference as Registration Barriers Reach "Insane" Levels

Notified -

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction

Notified -

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Notified -